Skip to main content

Table 5 Multivariate analysis of risk factors for infection after heart transplantation

From: Ventricular assist devices as bridge to heart transplantation: impact on post-transplant infections

  Bacterial and candida infection All fungal infections Viral infections
  Hazard ratio 95 % CI p-value Hazard ratio 95 % CI p-value Hazard ratio 95 % CI p-value
Recipient agea 0.89 0.67-1.19 0.43 1.30 0.77-2.21 0.32 0.91 0.68-1.20 0.49
Recipient male gender 2.06 0.85-5.01 0.11 0.98 0.22-4.32 0.98 1.59 0.62-4.10 0.33
Donor agea 1.03 0.81 – 1.31 0.81 1.10 0.74 – 1.63 0.64 0.92 0.70 – 1.20 0.54
Donor male gender 1.88 0.91 – 3.89 0.09 0.76 0.27 – 2.20 0.62 0.50 0.23 – 1.06 0.07
VAD pre-transplant     0.27b 0.06-1.30 0.10    
 - Continuous-flow device 0.94 0.38- 2.32 0.89     0.91 0.32 – 2.56 0.86
 - Other device 0.45 0.15 - 1.34 0.15     0.64 0.18 – 2.22 0.48
Diabetes 1.48 0.69-3.20 0.32 2.74 0.87-8.57 0.08 2.01 0.82-5.31 0.12
Post-transplant cotrimoxazole prophylaxis 0.29 0.15-0.57 <0.001 1.04 0.36-3.01 0.95 1.03 0.49-2.17 0.94
Transplant center          
 Center A (ref.) 1    1    1   
 Center B 0.69 0.32 – 1.49 0.35 1.38 0.40-4.78 0.61 1.06 0.46-2.45 0.89
 Center C 0.55 0.23 – 1.31 0.18 0.28 0.04-1.78 0.18 0.50 0.18-1.44 0.20
Induction therapy          
 No induction(ref.) 1    1    1   
 ATG 1.01 0.35 – 2.96 0.98 0.18 0.02-1.37 0.10 1.20 0.34-4.25 0.78
 Basiliximab 1.57 0.42 – 5.92 0.50 0.40 0.03-5.58 0.50 - - -
Use of everolimus 0.34 0.08 – 1.49 0.15 2.24 0.54-9.33 0.27 0.90 0.28-2.86 0.86
  1. VAD ventricular-assist device, ATG anti-thymocyte globulin
  2. aFor ten years age difference
  3. bNo patient in the “other device” group developed a fungal infection, so the specific hazard ratio for this subgroup could not be calculated